disease

The trial found patients taking the drug experienced a 17% relative improvement in their ability to force air out of their lungs in one second, a common measure of success in treating lung disease, compared with those on a placebo

Vertex's trial would have been deemed a success if it had delivered just a 4.5% improvement in the lung function test.

Shares of Vertex Pharmaceuticals (NASDAQ:VRTX) are up over 14% today, after it announced positive clinical trial results for its cystic fibrosis fighting drug VX-770.

The company sees 2011 EPS estimates to $3.38 to $3.40, from $3.38 to $3.44 per share, vs.

Medtronic (NYSE:MDT) reported Q3 EPS of $0.86, ahead of consensus estimates of $0.84 per share. Revenues for the quarter rose 3% year-over-year to $3.96 billion, missing consensus estimates of $3.97 billion.

President and Chief Executive Officer of Seattle Genetics, commented: "The strong brentuximab vedotin data we reported during the fourth quarter of 2010 highlighted an important year for Seattle Genetics, and position the company

Seattle Genetics (NASDAQ:SGEN) reported a Q4 loss of $0.34 per share, narrower than consensus estimates for a loss of $0.38 per share. Revenues for the quarter fell 63% year-over-year to $8.1 million, missing consensus estimates o

The beatification set for May 1st comes on an accelerated schedule that began just weeks after John Paul's death in 2005, when his successor Pope Benedict XVI waived the traditional five year waiting period for sainthood after a c

The Vatican announced Friday that the late Pope John Paul II will be beatified this spring, putting him one step closer to sainthood.

InterMune (ITMN) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a marketing authorization for Esbriet (pi